You are hereSeptember 13, 2021 | Haematopoetic Stem Cells
Autologous Cell-based Treatment for Severe Acute Kidney Injury in a Human Patient
Review of “Acute kidney injury successfully treated with autologous granulocyte colony-stimulating factor-mobilized peripheral blood CD34-positive cell transplantation: A first-in-human report” from STEM CELLS Translational Medicine by Stuart P. Atkinson
Researchers led by Hiroyuki Suzuki (Shonan Kamakura General Hospital, Kamakura, Japan) recently established the therapeutic potential of CD34-positive cell-enriched human peripheral blood mononuclear cell transplantation as a treatment for acute kidney injury in an animal model . This research, and others using mesenchymal stem cells derived from bone marrow , umbilical cord  (See the STEM CELLSarticle here!), and adipose tissue  have provided evidence for the utility of cell-based therapies for acute kidney injury; however, heir application in human patients for this indication remains undescribed.
In a recent STEM CELLS Translational Medicine article , the Suzuki team describes the first case of granulocyte colony-stimulating factor (G-CSF)-mobilized autologous CD34-positive cell transplantation as a treatment for acute kidney injury in a single human patient.
The details of this article from Suzuki et al. include:
- This first case involved a male patient diagnosed with acute kidney injury with chronic ischemic renal damage due to refractory hypertension with microangiopathic hemolysis
- Intermittent hemodialysis improved some hypertension-related symptoms, although acute kidney injury persisted
- The authors collected G-CSF-mobilized CD34-positive cells from the patient and infused them directly into both renal arteries
- This represents the first case in a phase I/II clinical trial of autologous G-CSF-mobilized peripheral blood CD34-positive cell transplantation for severe acute kidney injury with a cell dose-escalating protocol to evaluate the safety and efficacy as primary and secondary endpoints, respectively
- Cell transplantation associated with transient fever and thrombocytosis but failed to prompt any major adverse events
- Cell transplantation led to improved kidney function in the long term (as evidenced by improved serum creatinine levels)
While this new study describes a single patient, the authors hope that the accumulation of data will provide further support for G-CSF-mobilized autologous peripheral blood CD34-positive cell transplantation as a safe and effective treatment for human patients with acute kidney injury.
For more on the therapeutic potential of this cell-based strategy for the treatment of severe acute kidney injury, stay tuned to the Stem Cells Portal!
- Ohtake T, Kobayashi S, Slavin S, et al., Human Peripheral Blood Mononuclear Cells Incubated in Vasculogenic Conditioning Medium Dramatically Improve Ischemia/Reperfusion Acute Kidney Injury in Mice. Cell Transplantation 2018;27:520-530.
- La Manna G, Bianchi F, Cappuccilli M, et al., Mesenchymal Stem Cells in Renal Function Recovery after Acute Kidney Injury: Use of a Differentiating Agent in a Rat Model. Cell Transplantation 2011;20:1193-1208.
- Morigi M, Rota C, Montemurro T, et al., Life-Sparing Effect of Human Cord Blood-Mesenchymal Stem Cells in Experimental Acute Kidney Injury. STEM CELLS 2010;28:513-522.
- Burgos-Silva M, Semedo-Kuriki P, Donizetti-Oliveira C, et al., Adipose Tissue-Derived Stem Cells Reduce Acute and Chronic Kidney Damage in Mice. PLOS ONE 2015;10:e0142183.
- Suzuki H, Ohtake T, Tsukiyama T, et al., Acute kidney injury successfully treated with autologous granulocyte colony-stimulating factor-mobilized peripheral blood CD34-positive cell transplantation: A first-in-human report. STEM CELLS Translational Medicine 2021;10:1253-1257.